Zuse Anne, Schmidt Peter, Baasner Silke, Böhm Konrad J, Müller Klaus, Gerlach Matthias, Günther Eckhard G, Unger Eberhard, Prinz Helge
Department of Biochemistry and Medical Genetics, Manitoba Institute of Cell Biology, CancerCare Manitoba, ON6010-675 McDermot Avenue, Winnipeg, Canada.
J Med Chem. 2007 Nov 29;50(24):6059-66. doi: 10.1021/jm0708984. Epub 2007 Oct 31.
Benzenesulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone were prepared and found to inhibit microtubule formation by an in vitro tubulin polymerization assay. Several analogues showed potent cytotoxic activity in an assay based on K562 leukemia cells with IC50 values of <100 nM. The methylamino analogue 14i was the most active compound in this assay (14i, IC50 K562: 0.05 muM). Antiproliferative activities of selected compounds were additionally evaluated against a panel of 12 tumor cell lines, including multi-drug-resistant phenotypes. All resistant cell lines were sensitive to these compounds. Concentration-dependent flow cytometric studies showed that KB/HeLa cells treated with selected compounds were arrested in the G2/M phases of the cell cycle. In competition experiments, these compounds strongly displaced radiolabeled colchicine from its binding site in the tubulin, showing IC50 values lower than that of colchicine. The results demonstrate that the antiproliferative activity is related to the inhibition of tubulin polymerization.
制备了萘并[2,3 - b]噻吩 - 4(9H) - 酮和9(10H) - 蒽酮的苯磺酸盐衍生物,并通过体外微管蛋白聚合试验发现它们能抑制微管形成。在基于K562白血病细胞的试验中,几种类似物显示出强效的细胞毒性活性,IC50值<100 nM。甲氨基类似物14i是该试验中活性最高的化合物(14i,IC50 K562:0.05 μM)。还针对包括多药耐药表型在内的一组12种肿瘤细胞系评估了所选化合物的抗增殖活性。所有耐药细胞系对这些化合物均敏感。浓度依赖性流式细胞术研究表明,用所选化合物处理的KB/HeLa细胞停滞在细胞周期的G2/M期。在竞争实验中,这些化合物能将放射性标记的秋水仙碱从其在微管蛋白中的结合位点强烈置换出来,显示出低于秋水仙碱的IC50值。结果表明,抗增殖活性与微管蛋白聚合的抑制有关。